MDGL
Madrigal Pharmaceuticals, Inc.
Set alert
430.36 USD -1.34 -0.31%
425.00 Day range 437.80
412.35 52-week range 602.83
- YTD
- -26.10%
- 1 year
- +0.66%
- Open
- 431.55
- Prev close
- 431.70
- Mkt cap
- 9.94B
- Vol
- 251.66K
- Avg vol
- 278.50K
- EPS
- -12.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 425.00
- High
- 437.80
- Forward P/E
- 44.71
- Beta
- -1.05
- Short ratio
- 7.90
- Inst. own
- 104.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 500.44
- 200-d avg
- 500.32
- 1y target
- 685.22
Key statistics
- Market cap
- 9.94B
- Enterprise value
- 9.48B
- Trailing P/E
- 0.00
- Forward P/E
- 44.71
- PEG ratio
- 0.00
- Price / sales
- 7.74
- Price / book
- 18.98
- EPS (TTM)
- -12.85
- Beta
- -1.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -25.32%
- Revenue (TTM)
- 1.28B
- Revenue growth
- 71.20%
- Free cash flow
- -80.47M
- Total cash
- 838.75M
- Total debt
- 347.75M
- Return on equity
- -53.31%
- Shares outstanding
- 23.10M
- Short % of float
- 11.17%
- 50-day average
- 500.44
- 200-day average
- 500.32
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 685.22 +59.2% upside
Now 430.36
- Target (low)
- 533.00
- Target (mean)
- 685.22
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -1.09.
Financials — quick view
MDGL Revenue — quarterly 364.25M
MDGL Net income — quarterly -57.94M
MDGL EPS — quarterly -1.99
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.86294 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -2.68 | -1.99 | +0.69 | +25.75% |
| May 6, 2026 | Mar 31, 2026 | -3.61 | -3.25 | +0.36 | +9.97% |
| Feb 19, 2026 | Dec 31, 2025 | 0.04 | -2.57 | -2.61 | -6,525.00% |
| Nov 4, 2025 | Sep 30, 2025 | -2.04 | -5.08 | -3.04 | -149.38% |
| Aug 5, 2025 | Jun 30, 2025 | -3.48 | -1.90 | +1.58 | +45.40% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Aug 4, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | main | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | init | — | Overweight |
| Jun 11, 2026 | B of A Securities | main | Neutral | Neutral |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- madrigalpharma.com
News
- Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know
- Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
- Baron Health Care Fund: Q3 2026 New Positions And Exits
- Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise
- Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)
- Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra
- Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
- Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target
Your note
Sign in to keep a note on MDGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Unknown | Stock Award(Grant) | Jun 16, 2026 | 0 |
| CRAVES FREDERICK B | Director | Sale | Mar 12, 2025 | 383,547 |
| DIER MARDI C | Chief Financial Officer | Sale | Mar 5, 2026 | 12,490 |
| FRIEDMAN PAUL A | Director | Sale | Jan 8, 2026 | 842,704 |
| HUNTSMAN CAROLE A | Officer | Sale | Mar 5, 2026 | 12,692 |
| KELLEY SHANNON T | General Counsel | Sale | Aug 16, 2026 | 11,474 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.28% | 2,143,131 | 922.32M | Jun 29, 2026 |
| RTW Investments LP | 8.63% | 1,993,687 | 858.00M | Jun 29, 2026 |
| Jupiter Topco LLC | 8.38% | 1,936,099 | 833.22M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.94% | 1,833,333 | 788.99M | Jun 29, 2026 |
| PAULSON & CO. INC. | 5.80% | 1,340,020 | 576.69M | Jun 29, 2026 |
| Blackrock Inc. | 5.20% | 1,200,770 | 516.76M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.53% | 584,997 | 251.76M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.44% | 563,117 | 242.34M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.83% | 423,142 | 182.10M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.47% | 338,602 | 145.72M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17% | 270,288 | 116.32M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.05% | 243,683 | 104.87M | Jun 29, 2026 |